Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS)-Related Remission: 2-Year Results from a Phase 3 Study. J of Skin 2018, 2 (S1), S17. https://doi.org/10.25251/skin.2.supp.17.